Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | CHAT | P28329 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228398 | 0.86 | CYP2A6 (0.64) | CYP2A6ACACBTAAR1TP53EGLN1 | |
| SCHEMBL5050178 | 0.86 | CYP2A6 (0.64) | CYP2A6ACACBTAAR1TP53EGLN1 | |
| SCHEMBL14596519 | 0.83 | HDAC8 (0.62) | HDAC8CHATKCNH2 | |
| SCHEMBL9509240 | 0.79 | CYP2A6 (0.56) | CYP2A6ACACBTAAR1TP53EGLN1 | |
| SCHEMBL13614130 | 0.78 | HDAC8 (0.46) | HDAC8CHATALDH1A1KCNH2 | |
| SCHEMBL5301567 | 0.78 | — | — | |
| SCHEMBL2831073 | 0.77 | TP53 (0.59) | CYP2A6ACACBTP53FFAR1ALDH1A1 | |
| SCHEMBL9328231 | 0.77 | CYP2A6 (0.54) | CYP2A6ACACBTAAR1TP53FFAR1 | |
| SCHEMBL9333011 | 0.77 | CYP2A6 (0.54) | CYP2A6ACACBTAAR1TP53EGLN1 | |
| SCHEMBL7503100 | 0.77 | CYP2A6 (0.54) | CYP2A6ACACBTAAR1TP53FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7611546-B2 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | L'OREAL S.A. (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090064423-A1 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | L'OREAL S.A. (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090064423-A1 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | KRT18, HADHB, KAT7 | CYP2A6 1512/4885HDAC8 608/4885ACACB 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.